Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Deferred Taxes (2021 - 2024)

Prime Medicine's Deferred Taxes history spans 4 years, with the latest figure at -$134000.0 for Q2 2024.

  • For Q2 2024, Deferred Taxes fell 532.26% year-over-year to -$134000.0; the TTM value through Mar 2025 reached -$134000.0, down 335.09%, while the annual FY2023 figure was -$279000.0, 71.06% up from the prior year.
  • Deferred Taxes reached -$134000.0 in Q2 2024 per PRME's latest filing, down from $134000.0 in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $1.2 million in Q4 2021 to a low of -$532000.0 in Q1 2022.
  • Average Deferred Taxes over 4 years is $0.0, with a median of -$121000.0 recorded in 2023.
  • The largest YoY upside for Deferred Taxes was 166.34% in 2024 against a maximum downside of 532.26% in 2024.
  • A 4-year view of Deferred Taxes shows it stood at $1.2 million in 2021, then plummeted by 116.25% to -$202000.0 in 2022, then surged by 46.53% to -$108000.0 in 2023, then dropped by 24.07% to -$134000.0 in 2024.
  • Per Business Quant, the three most recent readings for PRME's Deferred Taxes are -$134000.0 (Q2 2024), $134000.0 (Q1 2024), and -$108000.0 (Q3 2023).